

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION NUMBER: **10/643,801**
FILING DATE: **8/18/2003**
FIRST NAMED INVENTOR: **Sanjay Bhanot**
ART UNIT: **1635**
EXAMINER NAME: **Jon E. Angell**
CONFIRMATION NUMBER: **4755**
ATTORNEY DOCKET NUMBER: **RTS-0678US**
TITLE: **MODULATION OF DIACYLGLYCEROL
ACYLTRANSFERASE 2 EXPRESSION**

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
Under 37 C.F.R. §§ 1.56 and 1.97-98

Dear Examiner Chong:

Pursuant to the provisions of 37 C.F. R. §§ 1.56 and 1.97-98, enclosed herewith is PTO Form PTO/SB/08A and PTO/SB/08B listing references for consideration by the Examiner.


The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

This Information Disclosure Statement is being filed before the mailing date of a first office action on the merits. Enclosed is a copy of each listed reference that may be material to the examination of this application, and for which there may be a duty to disclose.

Applicant submits that no fee is required for the consideration of this Information Disclosure Statement. However, if a fee is due, the Commissioner is hereby authorized to charge Deposit Account No 500252 referencing case number RTS-0678US.

Consideration of the listed references is respectfully requested.

Respectfully submitted,



Dated: 4/23/09

Reena R. Desai, Esq.
Registration No.: **53,833**
Isis Pharmaceuticals, Inc.
1896 Rutherford Road
Carlsbad, CA 92008